Qingdao Central Hospital
34
7
8
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 34 trials
100.0%
+13.5% vs industry average
21%
7 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (34)
Tirofiban After Successful MT Recanalization in AIS
Role: collaborator
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
Role: lead
Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction
Role: lead
Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions
Role: lead
Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer
Role: lead
QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC
Role: collaborator
Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study
Role: collaborator
Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
Role: collaborator
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
Role: lead
Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer
Role: lead
Nutrition Impact on Immunotherapy of Cancer
Role: lead
Normobaric Hyperoxia Combined With Endovascular Treatment in Acute Ischemic Stroke (OPENS-2)
Role: collaborator
SPT-07A Injection in Patients With Acute Ischemic Stroke (AIS): A Phase III Clinical Trial
Role: collaborator
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma
Role: lead
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Role: lead
Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab
Role: lead
Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer
Role: lead
Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer
Role: lead
Maintenance Therapy for Small-cell Lung Cancer
Role: lead
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer
Role: lead